New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:41 EDTGMED, BAXS, OSIR, NUVA, SNN, SMA, MDXG, RTIX, CNMD, AXGN, ANIK, BONECanaccord to hold a conference
Musculoskeletal Conference is being held in New Orleans, Louisiana on March 11.
Check below for free stories on GMED;ANIK;AXGN;CNMD;RTIX;MDXG;SMA;SNN;NUVA;OSIR;BAXS;BONE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
16:23 EDTMDXGMiMedx sees operating profit for Q3, consensus 0c
Sees Q3 revenue $30M-$32M, consensus $27.45M.
16:22 EDTMDXGMiMedx raises FY14 revenue view to $110M-$115M from $105M-$110M
Subscribe for More Information
16:21 EDTMDXGMiMedx reports Q2 EPS 0c, consensus 0c
Subscribe for More Information
July 24, 2014
08:19 EDTNUVA, GMEDLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
08:09 EDTRTIXRTI Surgical sees Q3 EPS 2c, consensus 2c
Subscribe for More Information
08:08 EDTRTIXRTI Surgical raises FY14 EPS ex-items 9c-11c from 7c-9c, consensus 8c
Subscribe for More Information
08:07 EDTRTIXRTI Surgical reports Q2 EPS 3c, consensus 2c
Reports Q2 revenue $66M, consensus $59.20M.
July 23, 2014
16:00 EDTCNMDCONMED price target lowered to $43 from $50 at Piper Jaffray
Subscribe for More Information
08:02 EDTMDXGMiMedx files its initial investigational New Drug Application
Subscribe for More Information
07:31 EDTBONEBacterin announces 1 for 10 reverse split of common stock
Bacterin announced that a 1:10 reverse split of its common stock will be effective at the close of business on Friday, July 25 and in effect for trading purposes on Monday, July 28. The reverse stock split was approved by the company's shareholders at the 2014 Annual Shareholder's Meeting held June 11.
07:09 EDTCNMDCONMED lowers FY14 adjusted EPS view to $1.85-$1.95 from $1.90-$2.00
Subscribe for More Information
07:06 EDTCNMDCONMED reports Q2 adjusted EPS 47c, consensus 47c
Subscribe for More Information
07:05 EDTCNMDCONMED CEO Corasanti steps down, Curt Hartman appointed Interim CEO
Subscribe for More Information
06:58 EDTCNMDCONMED trading halted, pending news
Subscribe for More Information
July 21, 2014
18:00 EDTBONEBacterin reports preliminary Q2 revenue $8.75M-$8.85M, consensus $8.93M
The company sees preliminary Q2 operating loss ($1.5M)-($1.4M). The company sees preliminary Q2 EBITDA of ($800K)-($900K). Gross margin for Q2 is expected to be 61%-63%.
July 18, 2014
07:34 EDTBAXSBaxano Surgical says economic analysis of the AxiaLIF accepted for publication
Baxano Surgical announced that the Journal of Managed Care Medicine, a peer-reviewed national publication, has accepted an economic analysis of the AxiaLIF pre-sacral interbody fusion procedure in comparison to transforaminal lumbar interbody fusion, or TLIF. The analysis, conducted by Scott Parker, MD, Director of the Spinal Column Surgical Quality and Outcomes Research Laboratory at Vanderbilt University, and Dr. Matt McGirt, Carolina Neurosurgery and Spine Associates, Adjunct Associate Professor, University of North Carolina, analyzed the bibliography for AxiaLIF and TLIF procedures and assessed relative costs by looking at reoperation rates, complication rates, blood loss and OR time. The study found that AxiaLIF resulted in an approximately $4,500 lower cost per procedure when looking at these procedural parameters.
July 16, 2014
07:18 EDTNUVA, GMEDScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 15, 2014
10:00 EDTMDXGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTMDXGMiMedx initiated with a Buy at Needham
Subscribe for More Information
July 14, 2014
10:56 EDTMDXGMiMedx says EpiFix addded as covered product in Jurisdiction H
MiMedx Group announced that the Medicare Administrative Contractor responsible for Jurisdiction H, which has approximately five million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas, has revised its Local Coverage Determination, LCD, for bioengineered skin substitutes in the hospital outpatient and physician office settings to include EpiFix. The revision to the LCD, entitled Bioengineered Skin Substitutes, names MiMedx's wound care allograft, EpiFix, as eligible for Medicare coverage when medically necessary and reasonable, subject to the coverage indications and limitations set forth in the LCD. The revision was published on July 10, effective for dates of service on or after June 16. Parker H. "Pete" Petit, Chairman and CEO, said, "As we discussed in our shareholder call on April 25, the contractor for Jurisdiction H previously had issued a draft consolidated LCD under which all skin substitutes with a Q-code were eligible for coverage if the case met the medically necessary and reasonable threshold. This LCD was to go into effect on March 27. On the effective date, the draft LCD was rescinded, and the contractor reverted to the previous LCD. The previous Jurisdiction H LCD covered only a few named skin substitutes and did not include coverage for EpiFix. In the update issued on July 10, the contractor has added EpiFix as a covered product. EpiFix was the only product added in that update. We are very pleased that EpiFix has been included in the revised LCD for this Medicare jurisdiction."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use